Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2022 | Blood-based biomarkers for Alzheimer’s disease screening

The availability of a blood biomarker for the diagnosis of Alzheimer’s disease is highly anticipated. Giovanni Frisoni, MD, University of Geneva, Geneva, Switzerland, discusses how blood-based biomarkers will be used in clinical practice. Although initial research focused on using such biomarkers for the diagnosis of Alzheimer’s disease, data available indicates that blood-based biomarkers could be used as a screening tool. If a screening test becomes available only if the test results are abnormal, further testing, such as PET scans and lumbar punctures, would be needed. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.